



65 West Watkins Mill Road
Gaithersburg, MD 20878
tel: 240-632-0740
fax: 240-632-0735
www.genvec.com

FOR IMMEDIATE RELEASE:

Investor Contact:

GenVec, Inc.
Danielle M. DiPirro
(301) 944-1877
ddipirro@genvec.com

Media Contact:

Tiberend Strategic Advisors, Inc.
Andrew Mielach
(212) 827-0020
amielach@tiberendstrategicadvisors.com

GENVEC ANNOUNCES FIRST QUARTER 2010 RESULTS CONFERENCE CALL

GAITHERSBURG, MD – April 27, 2010 – GenVec, Inc. (Nasdaq: GNVC) announced that it will release financial results for the first quarter ended March 31, 2010 on Thursday, May 6, 2010 after market close. GenVec will hold a conference call at 10:00 a.m. EDT on Friday, May 7, 2010 to discuss the Company’s first quarter results and provide an update on the Company’s corporate strategy.

To listen to the live conference call, please dial 877-558-0567 (U.S. or Canada) or 706-643-4980 (international) and use the following Conference ID: 72058383. An audio replay of the conference call will be available starting at 11:00 a.m. EDT on May 7, 2010 through May 14, 2010. To listen to the audio replay, dial 800-642-1687 or 706-645-9291.

A live webcast of the conference call will be available on the Company’s website and will be archived for 30 days. To access the webcast or the replay, go to www.genvec.com, click on “Investor Relations,” and click on “Webcasts and Data.”

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec uses its proprietary adenovector technology to develop TNFerade for the treatment of certain cancers and vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. GenVec also discovers and develops novel treatments for hearing loss and balance disorders through a worldwide collaboration with Novartis. Additional information about GenVec is available at www.genvec.com and in the Company’s various filings with the Securities and Exchange Commission.

###